NEW YORK CITY, NY / ACCESS Newswire / November 18, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ:IONS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Ionis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 9, 2026, Ionis disclosed that the late-stage Phase-3 CARDIO-TTransform trial of Wainua, an amyloid cardiomyopathy treatment developed in collaboration with AstraZeneca, did not meet its primary endpoint.
On this news, Ionis's stock price fell $20.19 per share, or 23.9%, to close at $64.27 per share on July 9, 2026.
Then, on November 9, 2026, Ionis announced its third quarter 2026 results, including that TRYNGOLZA sales for hypertriglyceridemia had "been more gradual than anticipated", with third quarter TRYNGOLZA sales reaching just $9 million. The Company also lowered its full-year TRYNGOLZA sales guidance to $50 million from $100 million to $110 million.
On this news, Ionis's stock price fell $8.42 per share, or 21.36%, to close at $31.00 per share on November 9, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Pomerantz LLP
View the original press release on ACCESS Newswire